Never too early: Why patient capital is essential for building Saudi biotech

One of the most common arguments raised about the biotech industry is that it is still too early to invest. This view misunderstands how biotechnology ecosystems are built. In biotech, waiting does not reduce risk; it simply hands leadership to those willing to commit earlier.

Saudi Arabia has already made its strategic intent clear through its National Biotechnology Strategy. Biotech is no longer experimental or peripheral. It is a core sector linked to health security, industrial development, and economic diversification. The real question now is not timing, but conviction.

Biotechnology does not reward short-term capital or rapid exit expectations. It rewards patience, discipline, and an understanding of milestone-based value creation. Clinical validation, regulatory approval, and scalable platforms matter more than speed. 

Biotech is a core  sector linked to health  security, industrial  development,  and economic  diversification. 

 

The belief that ecosystems must mature before investment begins is misplaced. Maturity is the outcome of patient capital, not its prerequisite. Every globally relevant biotech hub was shaped by investors who entered before outcomes were obvious and stayed through uncertainty.

Saudi Arabia’s advantage lies in alignment. The Kingdom can coordinate capital, policy, and infrastructure at scale — a structural strength few markets possess. When patient capital is paired with localization, biotech moves from imported innovation to domestic capability.

Patient capital is not passive. It is actively engaged in governance, talent selection, regulatory strategy, and global partnerships. Capital alone does not de-risk biotech; experience and long-term commitment do.

Those waiting for perfect clarity will miss the opportunity to shape the ecosystem. By the time biotech feels comfortable, leadership positions will already be occupied.

It is never too early to invest in biotech. It is only too late to lead once patience has run out.

• Dr. Huda Alfardus is a businesswoman and biotech investment expert focused on innovation, venture capital, and expanding women’s participation in business and investment markets.